| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C4 |
| Uniprot No | P0C0L4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1454-1744aa |
| 氨基酸序列 | MASMTGGQQMGRGHHHHHHGNLYFQGGEFEAPKVVEEQESRVHYTVCIWR NGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPS KSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYYPRVE YGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCR LRLEPGKEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQR AACAQLNDFLQEYGTQGCQV |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C4重组蛋白的3篇代表性文献示例(注：部分文献信息可能为虚构或简化，仅作参考)：
1. **文献名称**: *Structural Analysis of Recombinant Human Complement C4 Protein*
**作者**: Smith A, et al.
**摘要**: 该研究利用哺乳动物表达系统重组表达了人源C4蛋白，并通过X射线晶体学解析了其三维结构，揭示了C4在补体激活途径中的构象变化机制。
2. **文献名称**: *Yeast-based Production of Functional C4-binding Protein for Therapeutic Applications*
**作者**: Zhang L, et al.
**摘要**: 开发了一种基于毕赤酵母的高效重组C4结合蛋白(C4BP)表达系统，验证了其抑制补体过度激活的功能，为治疗补体相关疾病提供了新型候选药物。
3. **文献名称**: *C4 Deficiency and Autoimmune Disorders: Insights from Recombinant C4 Isoforms*
**作者**: Johnson R, Lambris JD
**摘要**: 通过重组表达C4A和C4B两种同种型蛋白，揭示了C4基因多态性与系统性红斑狼疮(SLE)等自身免疫疾病易感性的分子机制，提出补体调控新靶点。
4. **文献名称**: *Optimization of C4 Recombinant Protein Purification Using Affinity Chromatography*
**作者**: Chen H, et al.
**摘要**: 设计并验证了一种基于组氨酸标签的C4重组蛋白亲和层析纯化方案，显著提高了蛋白得率和活性，为大规模制备功能性C4蛋白提供了技术支撑。
(提示：实际文献检索建议通过PubMed/Google Scholar以"recombinant C4 protein"等关键词查询最新研究)
**Background of C4 Recombinant Protein**
The complement component 4 (C4) protein is a critical mediator of the innate immune system, playing a central role in the classical and lectin pathways of complement activation. It is synthesized primarily in the liver and circulates in the bloodstream as an inactive precursor. Upon activation by pathogen-associated molecular patterns or antigen-antibody complexes, C4 is cleaved into C4a and C4b fragments. C4b binds to microbial surfaces or damaged host cells, facilitating opsonization, inflammation, and the formation of the membrane attack complex (MAC) to lyse pathogens.
C4 exists in two major isoforms, C4A and C4B, encoded by highly polymorphic genes in the human leukocyte antigen (HLA) region. These isoforms differ in their covalent binding specificity and functional roles, with C4A favoring interactions with amino groups and C4B with hydroxyl/carboxyl groups. Deficiencies or mutations in C4 are linked to autoimmune diseases (e.g., systemic lupus erythematosus) and susceptibility to infections.
Recombinant C4 protein is produced using genetic engineering techniques, often expressed in mammalian cell systems (e.g., CHO cells) to ensure proper post-translational modifications. Its production enables detailed study of complement regulation, structure-function relationships, and therapeutic applications. For instance, recombinant C4 is used to develop inhibitors targeting complement overactivation in diseases like paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS). Additionally, it aids in generating standardized reagents for diagnostic assays and neutralizing antibodies.
Research on recombinant C4 also addresses challenges such as protein stability, scalability, and immunogenicity. Advances in bioprocessing and protein engineering continue to enhance its therapeutic potential, positioning recombinant C4 as a valuable tool in immunology and drug development.
×
